Given that these three molecules are implicated in partially overlapping yet distinct aspects of tumor progression, a combinatorial therapeutic strategy that simultaneously targets CSPG4, xCT, and TLR2 may represent a novel and more effective approach to disrupt multiple tumor-supportive mechanisms. This evidence concerns the gene CSPG4 and neoplasm.